Bioequivalence of 150 mg Extended-Release Ketoprofen from Laboratories LETI S.A.V. Test, vs ProfenidBI of Laboratories Sanofi-Aventis Pharmaceuticals LTDA, Prolonged Release, Reference, in Healthy Volunteers*
Objective: To evaluate the
bioequivalence between two formulations of ketoprofen after administration of a
150 mg extended release tablet (L.P. ProfenidBI？), 150 mg modified release
tablets. Methods: A single-dose cross-over, randomized study was
performed under fasting conditions with two treatments, two periods, two
sequences (2 × 2) with a 7-day washout period between each dose in 28 healthy
volunteers. Subjects were randomly assigned to each of the administration
sequences. The pharmacokinetic parameters evaluated were: Cmax,
AUC0-t and AUC0-∞. For the bioequivalence
analysis, the AUC0-t was calculated from the time of
administration to the 12th hour, posology requested for the
medication test, by the trapezoidal method; Software: Excel. The means and
Confidence Intervals were compared between 80% - 125% for the quotient
of Cmax, Tmax, AUC0-t and
AUC0-∞. Results: Cmax 8.3529 ± 1.9176 μg/mL vs.
7.7175 ± 2.1751 μg/mL, Tmax 0.75 h vs. 1.25 h, AUC0-12 25.9560 ± 4.9846 μg/mL/hr vs. 24.9015 ± 5.1507 μg/mL/ hr and AUC0-∞ 27.0147 ± 5.1099 μg/mL/hr vs. 25.6400 ± 5.1144 μg/mL/h, respectively. 95% IC: Cmax 106.26% - 107.85%, AUC0-12 101.11% - 101.78% and AUC0-∞ 100.53% - 102.94%. Conclusion:
The test formulation Ketoprofen 150 mg LP, manufactured by LETI S.A.V.
Laboratories, is bioequivalent with respect to the reference product ProfenidBI 150 mg controlled release tablets, manufactured by Sanofi-Aventis
Pharmaceuticals LTDA Laboratories, as the Values obtained from AUC and Cmax were maintained in the range of 80% - 125%.
Cite this paper
Annunziato, M. A. , Yibirin, M. G. , Alfredo, I. and Soler, M. M. (2018). Bioequivalence of 150 mg Extended-Release Ketoprofen from Laboratories LETI S.A.V. Test, vs ProfenidBI of Laboratories Sanofi-Aventis Pharmaceuticals LTDA, Prolonged Release, Reference, in Healthy Volunteers*. Open Access Library Journal, 5, e4366. doi: http://dx.doi.org/10.4236/oalib.1104366.
Roda, A., et al. (2002) Bioavailability of a New Ketoprofen Formulation for Once-Daily Oral Administration. International Journal of Pharmaceutics, 241, 165-172.
Bryson, P.D. (1996) IX Agents for pain: Nonsteroidal Anti-Inflammatory Agents. Characteristics of the NSAIDs. In: Bryson, P.D., Ed., Comprehensive Review in Toxicology for Emergency Clinicians, 3rd Edition, Taylor & Francis, Washington DC, 571.
Hauschke, D., Steinijans, V.W., Diletti, E. and Burke, M. (1992) Sample Size Determination for Bioequivalence Assessment Using a Multiplicative Model. Journal of Pharmacokinetics and Biopharmaceutics, 20, 557-561.
Houghton, G.W., et al. (1984) Comparative Pharmacokinetics of Ketoprofen Derived from Single Oral Doses of Ketoprofen Capsules or a Novel Sustainedreleasepellet Formulation. Biopharmaceutics & Drug Disposition, 5, 203-209.
Greene, W.L., Concato, J. and Feinstein, A.R. (2000) Claims of Equivalence in Medical Research: Are They Supported by the Evidence? Annals of Internal Medicine, 132, 715-722.
Song, F., Altman, D., Glenny, A. and Deeks, J. (2003) Validity of Indirect Comparison for Estimating Efficacy of Competing Interventions: Empirical Evidence from Published Meta-Analyses. BMJ, 326, 472.